AGXT rs180177189: Understanding Primary Hyperoxaluria Type 1
The rs180177189 variant is a specific genetic change located within the AGXT gene. It is associated with primary hyperoxaluria type 1 (PH1), a rare inherited condition that affects how the body processes glyoxylate, often leading to kidney stones and potential renal complications.
What each genotype means
Typical enzyme function
This is the reference genotype, meaning you carry the common version of the AGXT gene. It is not associated with the development of primary hyperoxaluria type I.
This is the most common genotype found in the general population.
Carrier of variant
You carry one copy of the pathogenic variant associated with primary hyperoxaluria type I. Because this condition is inherited in an autosomal recessive manner, carrying a single copy typically does not cause the disease, but you should consult with a genetic counselor regarding family planning.
This genotype is rare in the general population.
Increased risk of hyperoxaluria
You carry two copies of this pathogenic variant, which is associated with primary hyperoxaluria type I. This condition can lead to the overproduction of oxalate, potentially causing kidney stones and impaired kidney function; please discuss these results with a medical professional or specialist.
This genotype is extremely rare in the general population.
What is the rs180177189 Variant?
The rs180177189 variant is a single-nucleotide polymorphism (SNP) found within the AGXT gene, which is located on chromosome 2. In the context of human genetics, SNPs represent the most common type of genetic variation, where a single building block of DNA—a nucleotide—is replaced by another. For rs180177189, this change occurs in the sequence that provides instructions for building the alanine:glyoxylate aminotransferase (AGT) enzyme. Because this gene is critical for metabolic processes in the liver, variations here can disrupt the normal function of the enzyme. Researchers track these specific variants to understand how they contribute to rare metabolic disorders. While many variants in the AGXT gene are benign, some, like those categorized as pathogenic, can significantly alter the protein's structure or stability, leading to the clinical manifestations observed in patients with primary hyperoxaluria.
The Role of the AGXT Gene
The AGXT gene provides the blueprint for the alanine:glyoxylate aminotransferase (AGT) enzyme. This enzyme is primarily active in the liver, where it resides within peroxisomes—small structures inside cells that break down various substances. The main job of AGT is to convert a compound called glyoxylate into glycine. When the AGXT gene contains a pathogenic mutation, the resulting AGT enzyme may be missing, inactive, or misdirected to the wrong part of the cell. Without functional AGT, glyoxylate accumulates and is instead converted into oxalate. Oxalate is a substance that the body cannot easily process; it binds with calcium to form calcium oxalate crystals. These crystals can accumulate in the kidneys and bladder, leading to the formation of stones and, over time, potentially causing significant damage to kidney tissue and overall renal function.
Research and Clinical Associations
Scientific research has established a strong link between mutations in the AGXT gene and primary hyperoxaluria type 1 (PH1). PH1 is an autosomal recessive disorder, meaning an individual typically needs to inherit two copies of a pathogenic variant—one from each parent—to manifest the condition. The evidence for the pathogenicity of various AGXT variants is supported by clinical studies, including those published in journals like Scientific Reports and the Journal of Medical Genetics. Researchers use molecular studies to observe how specific mutations, such as those affecting the active site of the AGT enzyme, lead to a loss of catalytic efficiency. While some variants are well-documented, others are identified through case reports of affected families. The strength of the association between a specific variant and the disease is determined by clinical observation, biochemical testing of enzyme activity, and genetic screening of affected individuals and their relatives.
Population Frequency and Genetic Context
Primary hyperoxaluria type 1 is considered a rare condition, and the frequency of specific pathogenic variants like rs180177189 can vary significantly across different global populations. Many AGXT mutations are rare, and there is no single, universal frequency for this specific variant across all ancestries. In many cases, pathogenic variants in AGXT are identified in the context of clinical diagnosis rather than broad population screening. Because PH1 is autosomal recessive, the presence of a single copy of a pathogenic variant in a person (a carrier) usually does not cause symptoms. Genetic heterogeneity is a hallmark of this condition, meaning that different families may carry different mutations within the same gene. Consequently, population-wide frequency data for rare variants is often limited, and clinical geneticists rely on targeted testing when a patient presents with symptoms of recurrent kidney stones or unexplained renal failure.
Navigating Genetic Information
Understanding your genetic information requires careful interpretation in consultation with healthcare professionals. If you or a family member have been identified as a carrier of an AGXT variant, or if you are experiencing symptoms such as recurrent kidney stones, it is essential to speak with a medical geneticist or a nephrologist. Genetic testing can provide clarity, but it should always be accompanied by professional genetic counseling to discuss the implications for your health and your family. You cannot diagnose yourself based on a single SNP result. If a pathogenic variant is confirmed, your medical team will guide you through appropriate monitoring, such as urine and blood tests, to assess kidney function and oxalate levels. Never make changes to your health management or diet based solely on genetic data without first discussing the findings with a qualified clinician who understands your full medical history.
How common is this variant?
The frequency of this variant is not widely recorded in general population databases, as it is a rare mutation associated with a specific clinical condition.
Frequently asked questions
What is primary hyperoxaluria type 1?
Primary hyperoxaluria type 1 is a rare, inherited metabolic disorder caused by a deficiency of the liver enzyme AGT. This deficiency leads to the overproduction of oxalate, which can cause kidney stones and progressive kidney damage.
Is rs180177189 a cause of kidney stones?
The variant is associated with the genetic condition that causes primary hyperoxaluria, which in turn leads to the formation of calcium oxalate kidney stones. However, most kidney stones are caused by factors other than this specific genetic variant.
Should I get tested for AGXT variants?
Genetic testing for AGXT is typically recommended by a doctor if there is a clinical suspicion of primary hyperoxaluria, such as a history of recurrent kidney stones or a family history of the condition. You should discuss the necessity of testing with a nephrologist or genetic counselor.
Can I treat this variant with diet?
Dietary changes are often part of the management plan for patients with primary hyperoxaluria to help reduce oxalate intake, but they do not correct the underlying genetic cause. Any dietary or medical management must be directed by your healthcare provider.
Sources & further reading
Educational information only, last refreshed 10/3/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs180177189?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29